z-logo
open-access-imgOpen Access
Relationships between Chromosome 7 Gain, MET Gene Copy Number Increase and MET Protein Overexpression in Chinese Papillary Renal Cell Carcinoma Patients
Author(s) -
Xiaolu Yin,
Tianwei Zhang,
Xinying Su,
Yan Ji,
Ye Peng,
Haihua Fu,
Shuqiong Fan,
Yanying Shen,
Paul R. Gavine,
Yi Gu
Publication year - 2015
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0143468
Subject(s) - copy number variation , fluorescence in situ hybridization , papillary renal cell carcinomas , biology , immunohistochemistry , chromosome , gene dosage , cancer research , chromosome 17 (human) , chromosome 7 (human) , microbiology and biotechnology , gene , pathology , gene expression , carcinoma , medicine , genetics , immunology , genome
To investigate the relationships between Chromosome 7 gain, mesenchymal-epithelial transition factor ( MET) gene copy number increase and MET protein overexpression in Chinese patients with papillary renal cell carcinoma (PRCC), immunohistochemistry (IHC), immunofluorescence (IF) and fluorescence in situ hybridization (FISH) were performed on 98 formalin-fixed, paraffin-embedded (FFPE) PRCC samples. Correlations between MET gene copy number increase, Chromosome 7 gain and MET protein overexpression were analyzed statistically. A highly significant correlation was observed between the percentage of tumor cells with MET gene copy number ≥3 and CEP7 copy number ≥3 (R 2 = 0.90, p <0.001) across two subtypes of PRCC. In addition, the percentage of tumor cells with MET gene copy number ≥3 was found to increase along with increases in MET IHC score. This correlation was further confirmed in those PRCC tumor cells with average MET gene copy number >5 using combined IF and FISH methodology. Overall, this study provides evidence that Chromosome 7 gain drives MET gene copy number increase in PRCC tumors, and appears to subsequently lead to an increase in MET protein overexpression in these tumor cells. This supports MET activation as a potential therapeutic target in sporadic PRCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom